EUVIMEDEUVIMED entdecken
Fallbericht

A case report of Isaacs’ syndrome with treatment-resistant pain responsive to rituximab

Berin Inan iD, Ulkuhan Duzgun iD, Semih Mert Kilic iD, Omer Karadas iD, Zeki Odabasi iD

Ideggyógyászati szemle · 2025

DOI: 10.18071/isz.78.0214 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Ideggyógyászati szemle, 2025. Verfasst von Berin Inan und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology, Gulhane Medical Faculty, University of Health Sciences, Turkey. Hauptthemen laut MEDLINE: Rituximab, Isaacs Syndrome, Immunologic Factors. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Isaacs’ syndrome is an immune-mediated primary peripheral nerve hyperexcitability syndrome characterized by muscle twitches, cramps, and muscle stiffness. In 30-50% of cases, antibodies against voltage-gated potassium channel (VGKC) complex proteins are present. Symptomatic treatment, intravenous immunoglobulin (IVIg), plasma exchange (PE), and intravenous methylprednisolone (IVMP) are generally effective in controlling symptoms. However, some cases remain treatment-refractory. We present a 52-year-old female patient with walking difficulty, fasciculations, and severe back and hip pain. The patient was positive for anti-VGKC antibodies with a history of thymoma. Symptomatic treatment, highdose IVMP, IVIg and PE treatments improved the patient’s gait partially but failed to control the pain and fasciculations. Eventually, we treated the patient with rituximab (RTX), because of its effect on antibody-mediated autoimmunity, resulting in complete symptomatic relief without side effects. RTX is a safe and effective option for controlling symptoms in treatment-refractory cases with Isaacs’ syndrome. Isaacs’ syndrome is an immune-mediated primary peripheral nerve hyperexcitability syndrome characterized by muscle twitches, cramps, and muscle stiffness. In 30-50% of cases, antibodies against voltage-gated potassium channel (VGKC) complex proteins are present. Symptomatic treatment, intravenous immunoglobulin (IVIg), plasma exchange (PE), and intravenous methylprednisolone (IVMP) are generally effective in controlling symptoms.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

RituximabIsaacs SyndromeImmunologic FactorsHumansFemaleMiddle AgedTreatment Outcome

Stichwörter der Autor:innen

Isaacs’ syndromemyokymianeuromyotoniapainrituximab

Substanzen

RituximabImmunologic Factors

Autor:innen und Institutionen

  • Department of Neurology, Gulhane Medical Faculty, University of Health Sciences, Turkey.

ORCID-Profile: Berin Inan, Ulkuhan Duzgun, Semih Mert Kilic, Omer Karadas, Zeki Odabasi

Zitieren

APA

Inan, B., Duzgun, U., Kilic, S. M., Karadas, O., & Odabasi, Z. (2025). A case report of Isaacs’ syndrome with treatment-resistant pain responsive to rituximab. Ideggyógyászati szemle. https://doi.org/10.18071/isz.78.0214

Vancouver

Inan B, Duzgun U, Kilic SM, Karadas O, Odabasi Z. A case report of Isaacs’ syndrome with treatment-resistant pain responsive to rituximab. Ideggyógyászati szemle. 2025. doi:10.18071/isz.78.0214

BibTeX
@article{Inan2025,
  author = {Inan, Berin and Duzgun, Ulkuhan and Kilic, Semih Mert and Karadas, Omer and Odabasi, Zeki},
  title = {A case report of Isaacs’ syndrome with treatment-resistant pain responsive to rituximab},
  journal = {Ideggyógyászati szemle},
  year = {2025},
  doi = {10.18071/isz.78.0214}
}
Kostenlos starten →